Vitestro
About
About Vitestro
Vitestro's Aletta automates a diagnostic blood draw from tourniquet placement through vein selection, needle insertion, tube changing and inversion, needle withdrawal and bandage application. Near-infrared imaging locates candidate vessels, ultrasound evaluates them and Doppler confirms that the selected target is a vein before the robot positions the needle with submillimetre precision.
A trained supervisor loads the collection tubes and can oversee as many as three devices, while patients receive step-by-step guidance and can pause or stop the procedure. Aletta uses a sterile needle for each draw and stores completed samples inside the unit for staff retrieval. The system is CE-marked for clinical use in the European Union and operates at Dutch hospital trial and early-adopter sites; it is not approved or sold in the United States.
Articles
Operations
Orders & commitments
- Order / commitment
2024-05-21 - Odense University Hospital signed a pre-order for three Vitestro autonomous blood-drawing devices, described by Vitestro as its first international deployment. - Vitestro autonomous blood-drawing devices
Source
Funding
Investors
- EIC Fund - Participant - VC - 2 funding events - repeat backer - first seen 2024-04-30 - latest 2026-03-10
- Invest-NL - Participant - Unknown - 2 funding events - repeat backer - first seen 2024-04-30 - latest 2026-03-10
- NYBC Ventures - Lead - VC - 2 funding events - repeat backer - first seen 2024-04-30 - latest 2026-03-10
- Sonder Capital - Lead - VC - 2 funding events - repeat backer - first seen 2024-04-30 - latest 2026-03-10
- Existing private investors - Participant - Unknown - 1 funding event - first seen 2024-04-30
- Fred Moll - Participant - Angel / Individual - 1 funding event - first seen 2026-03-10
- InterVest - Participant - Unknown - 1 funding event - first seen 2026-03-10
- Labcorp Venture Fund - Participant - VC - 1 funding event - first seen 2026-03-10
- Mayo Clinic - Participant - Angel / Individual - 1 funding event - first seen 2026-03-10
- MGFO - Participant - Unknown - 1 funding event - first seen 2026-03-10
- PGGM - Participant - Unknown - 1 funding event - first seen 2026-03-10
- Puma Venture Capital - Participant - VC - 1 funding event - first seen 2026-03-10
- ROM Utrecht - Participant - Angel / Individual - 1 funding event - first seen 2026-03-10
- Sutter Health - Participant - Angel / Individual - 1 funding event - first seen 2026-03-10
Team
- Toon Overbeeke - CEO & Co-founder - Leads Vitestro?s autonomous robotic phlebotomy device business and clinical adoption strategy.
- Brian Joseph - VP of Product Vision & Co-founder - Shapes Vitestro?s product direction for autonomous blood collection workflows.
- Bob Gerberich - Chief Commercial Officer - Leads Vitestro?s pre-launch market development and commercial execution across European and U.S. healthcare markets.
- Andy McGibbon - VP of Strategy and Business Development - Leads strategy and business development for Vitestro?s autonomous blood collection platform.
- Luuk Giesen - Chief Medical Officer - Leads clinical strategy for Vitestro?s autonomous venipuncture and diagnostic blood collection work.
Timeline
Events
- 2026-08-20 - Regulatory - Vitestro receives FDA De Novo authorization for Aletta
Aletta combines near-infrared, ultrasound and Doppler imaging with robotics and AI to identify veins, guide needle insertion and collect diagnostic samples. The authorization follows Aletta's CE marking and clinical and pre-commercial use in Europe. Vitestro said it will advance manufacturing scale-up and a U.S. multicenter clinical trial before a phased U.S. launch.
Source - 2026-04-14 - Capability - Vitestro publishes multicenter clinical study of autonomous robotic phlebotomy
The ADOPT study enrolled 1,633 patients across three outpatient phlebotomy departments in the Netherlands, with patient-acceptance data from Mayo Clinic. First-stick success reached 94.5% when a suitable vein was identified; hemolysis was 0.3% and adverse events were 0.6%, all mild. Ninety percent of patients reported pain less than, far less than or similar to manual phlebotomy, while 82% would prefer or had no preference for Aletta in future draws.
Source - 2026-03-10 - Funding - Vitestro raises $70M Series B to advance autonomous robotic phlebotomy and commercial readiness
Vitestro raised an oversubscribed $70M Series B to support the next generation of Aletta and broader commercial readiness. Proceeds will support U.S. FDA De Novo work, manufacturing scale-up, clinical expansion, and commercial infrastructure development. The round included strategic healthcare backers including Labcorp Venture Fund, Mayo Clinic, and Sutter Health alongside existing investors.
Source - 2024-08-28 - Regulatory - Vitestro achieves CE marking for autonomous blood drawing device
Vitestro announced CE marking for its autonomous blood drawing device under the European Medical Device Regulation. The approval cleared the device for commercial use across the European Union. The company said several devices had already been ordered and planned a limited market release over the following months.
Source - 2024-05-21 - Commercial Order - Danish hospital pre-orders 3 blood drawing devices in first international deployment for Vitestro
Odense University Hospital signed a pre-order for three Vitestro autonomous blood-drawing devices, marking Vitestro's first international customer commitment. The hospital planned to introduce the systems after CE marking, with pre-deployment workflow integration and training through Vitestro Academy. Vitestro's system combines AI-guided ultrasound and submillimetre needle insertion for supervised autonomous phlebotomy.
Source - 2024-04-30 - Funding - Vitestro secures $22 million (€20 million) for autonomous blood draw device
Vitestro announced a $22 million (€20 million) funding round for its autonomous blood draw device. The raise added capital ahead of CE-marking and broader commercialization. The round sits as the main disclosed funding event before the 2026 Series B.
Source - 2024-04-03 - Commercial Order - Vitestro secures order from Result Laboratorium for two blood drawing devices
Result Laboratorium ordered two Vitestro autonomous blood-drawing devices for its Dutch diagnostic laboratory network. The devices combine AI-guided ultrasound with submillimetre needle positioning and automate the blood-draw workflow through bandaging. Deployment was planned after CE marking, while Result Laboratorium remained a clinical-study site.
Source
Relations
Relationships
- Odense University Hospital
Autonomous Blood Drawing Customer - Odense University Hospital pre-ordered three Vitestro autonomous blood-drawing devices.